RxDoctor Payments Data

William Roche, MD

Clinical Neurophysiology · Macon, GANPI 1326396490

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $414 of the $474 with a category attached, or 87.4%. 8 manufacturers reported payments, led by AbbVie at 31.7% of the total. Reporting peaked in 2023 at $310 and has fallen 88.7% since, to $35 in 2025.

$474in general payments, 2019–2025

Across 25 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$151
  • Novartis$84
  • UCB, Inc.$82
  • Biogen$75
  • Amgen$28
  • AstraZeneca$25
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$41487%
  • Education$6013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie10$151
Novartis5$84
UCB, Inc.4$82
Biogen2$75
Amgen1$28
AstraZeneca1$25
Sanofi1$16
Pfizer1$14

How this compares

Too few clinical neurophysiology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$119,658
Medicare patients
338
Services billed
4,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5015$304,267
CopaxoneGlatiramer Acetate13$74,600
Emgality PenGalcanezumab-Gnlm57$38,746
Nurtec OdtRimegepant Sulfate27$26,546
Aimovig AutoinjectorErenumab-Aooe25$25,611
UbrelvyUbrogepant28$23,587
BotoxOnabotulinumtoxina17$19,804
RytaryCarbidopa/Levodopa32$9,333
Carbidopa-LevodopaCarbidopa/Levodopa253$9,034
Levetiracetam173$4,515
Rivastigmine23$4,401
Donepezil Hcl285$3,978
Pyridostigmine Bromide36$3,679
Memantine Hcl90$3,043
Rasagiline Mesylate13$2,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox$151$43,39245 claims
PfizerNurtec Odt$14$26,54627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →